The Hetero Ring Has Exactly 13 Ring Carbons (e.g., Erythromycin, Etc.) Patents (Class 514/29)
-
Publication number: 20130150315Abstract: The invention comprising the heretofore veterinary anti-protozoal decoquinate and one or both of a redox drug or macrolide drug for prophylaxis or treatment of Babesia and other Apicomplexan protozoa infections in humans. The decoquinate or its metabolite kill certain life stages of Babesia. The redox and macrolide drugs treat life stages and forms of Babesia that are not susceptible to the decoquinate.Type: ApplicationFiled: December 8, 2012Publication date: June 13, 2013Inventor: Mary C. Kline
-
Patent number: 8461120Abstract: The invention features novel macrocyclic compounds, methods of making the compounds, pharmaceutical compositions including the compounds, and methods of treatment using the compounds.Type: GrantFiled: July 30, 2010Date of Patent: June 11, 2013Assignee: Synovo GmbHInventors: Hans-Jurgen Gutke, Michael Burnet, Jan-Hinrich Guse
-
Patent number: 8445451Abstract: Macrolides of Formula (I) or (I-A): and wherein the residues R1, R2, R3, R4, R12, R13 and R14 have certain meanings defined in this application are useful for treating or preventing inflammatory or allergic diseases or, cancer in animals and humans.Type: GrantFiled: February 9, 2009Date of Patent: May 21, 2013Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
-
Publication number: 20130115192Abstract: This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly(ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization from” approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling to” that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonal” chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.Type: ApplicationFiled: November 2, 2012Publication date: May 9, 2013Applicant: BIND BIOSCIENCES, INCInventor: BIND BIOSCIENCES, INC
-
Publication number: 20130109617Abstract: Methods and compositions for the treatment of Bacillus anthracis infections are described.Type: ApplicationFiled: October 10, 2007Publication date: May 2, 2013Inventors: Michael N. Alekshun, S. Ken Tanaka
-
Publication number: 20130102550Abstract: This invention relates to a macrolide composition, more particularly an amorphous form (Form-III) of 3R, 4S, 5S, 6R, 7R, 9R, 11S, 12R, 13S, 14R-6-[(2S, 3R, 4S, 6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7, 12, 13-trihydroxy-4-[(2R, 4R, 5S, 6S)-5-hydroxy-4-methoxy-4, 6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxy-imino)-3, 5, 7, 9, 11, 13-hexamethyl-1-oxacyclotetradecan-2-one or roxithromycin characterised by the absence of peaks in the infra-red spectrum of amorphous (Form-III) of roxithromycin at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 relative to the infra-red spectrum of the prior art roxithromycin raw material displaying peaks at 3577.15; 3526.03; 3465.27 and 3276.24 cm-1 and further characterised by an increased solubility of at least 50% over prior art anhydrous and monohydrated roxithromycin in acetate buffer (pH 4.5), phosphate buffer (pH 6.8) and water.Type: ApplicationFiled: April 14, 2011Publication date: April 25, 2013Applicant: North-West UniversityInventors: Wilna Liebenberg, Marique Aucamp
-
Publication number: 20130101653Abstract: This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures.Type: ApplicationFiled: October 24, 2012Publication date: April 25, 2013Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventor: Mayo Foundation for Medical Education and Rese
-
Publication number: 20130102551Abstract: The invention relates to solid pharmaceutical or veterinary compositions comprising substantially pure Tulythromycin A in form of an addition salt with one or more acids, and to methods for preparing them. Following reconstitution with an aqueous solvent, the resulting solutions of Tulathromycin A may be administered to a mammal in order to treat bacterial or protozoal infections.Type: ApplicationFiled: June 30, 2011Publication date: April 25, 2013Inventors: Andreas Hotte, Johannes Ludescher, Rafael Garcia, Oriol Martorell, Albert Codony
-
Publication number: 20130084343Abstract: Methods of sepsis in a sample from a patient are provided. Methods of detecting changes in expression of one or more RNAs associated with sepsis are also provided. Compositions and kits are also provided.Type: ApplicationFiled: September 14, 2012Publication date: April 4, 2013Applicant: CEPHEIDInventors: David Vilanova, Olivier Delfour
-
Patent number: 8410065Abstract: The invention relates to antibiotic macrolides of formula (I), which have improved anti-inflammatory activity mediated through inhibition of phosphodiesterase 4 (PDE4) useful for the treatment and/or prevention of inflammatory, allergic and proliferative diseases.Type: GrantFiled: February 9, 2009Date of Patent: April 2, 2013Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
-
Publication number: 20130078256Abstract: The invention is related to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: November 20, 2012Publication date: March 28, 2013Applicant: Korea Research Institute of Chemical TechnologyInventor: Korea Research Institute of Chemical Technology
-
Publication number: 20130064772Abstract: Provided are wound caring compositions and devices containing a pH-sensitive, preferably acid degradable, components contained in a water-permeable and hydronium ion permeable material. The pH-sensitive component encloses an antibiotic which is released to the wound upon infection by a microorganism at the wound site, and/or encloses a pH indicator. The antibiotic release is triggered by the microorganism's production of CO2 at the wound site which forms carbonic acid, lowers the pH at the pH sensitive components, and thus results in rupture of the liposome.Type: ApplicationFiled: September 7, 2012Publication date: March 14, 2013Inventors: Gerald F. Swiss, Stefan Schwabe, Robert M. Moriarty
-
Publication number: 20130065845Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents.Type: ApplicationFiled: September 14, 2012Publication date: March 14, 2013Inventors: Ashoke Bhattacharjee, Zoltan F. Kanyo, Edward C. Sherer
-
Publication number: 20130065818Abstract: The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.Type: ApplicationFiled: October 26, 2012Publication date: March 14, 2013Applicant: POLYMEDIXInventor: PolyMedix
-
Publication number: 20130059805Abstract: The invention relates to an amorphous non-crystalline glass form (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-?-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-?-L-ribo-hexopyranoside or azithromycin having an infra-red pattern displaying characteristic relatively broad peaks at approximately 3500 and 1727 cm?1 and characteristic peaks at approximately 2970 and 2938 cm?1. The invention further relates to a preparation method of increasing the solubility of azithromycin including the steps of selecting anhydrous, monohydrated or dihydrated azithromycin; elevating the temperature of the azithromycin to above the melting point thereof; and reducing the temperature of the melt sufficiently to allow it to set into an amorphous non-crystalline glass form (Form-II) of azithromycin having relatively increased solubility without decreasing the structural stability thereof.Type: ApplicationFiled: December 15, 2010Publication date: March 7, 2013Applicant: North-West UniversityInventors: Roelf Willem Odendaal, Wilna Liebenberg, Marique Aucamp
-
Publication number: 20130059774Abstract: Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided.Type: ApplicationFiled: April 1, 2010Publication date: March 7, 2013Inventors: Mahesh Vithalbhai Patel, Sachin Subhash Bhagwat, Mohammad Alam Jafri
-
Patent number: 8383785Abstract: The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit superior antibacterial properties, particularly against Haemophilus influenzae. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.Type: GrantFiled: May 8, 2009Date of Patent: February 26, 2013Assignee: Enanta Pharmaceuticals, Inc.Inventors: Rajesh Iyengar, Yanchun Wang, Ly Tam Phan, Yat Sun Or
-
Publication number: 20130045938Abstract: A method of treating cancer in which a compound that inhibits the expression, production or release of IL-10 by immune cells is combined with a compound that stimulates the production of IL-12 when given in combination with, or in the presence of TNFa. Said method is effective when provided in addition to standard therapies, notably chemotherapy using cytotoxic drugs and other forms of immune therapy including therapeutic vaccines.Type: ApplicationFiled: August 15, 2012Publication date: February 21, 2013Applicant: Synovo GmbHInventors: Michael W. Burnet, Jan-Hinrich Guse, Christiane Bauerlein, Ulrike Hahn
-
Publication number: 20130045936Abstract: The invention relates to an amorphous non-crystalline glass form (Form-ll) of 3R,4S,5S,6R,7R,9R,11S,12R,13S,14R-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-1-oxa-cyclotetradecan-2-one or roxithromycin having at least one characteristic infra-red spectrum peak at approximately 3580 to 3464 cm?1. The invention further relates to a preparation method of increasing the solubility of roxithromycin including the steps of selecting anhydrous roxithromycin or monohydrated roxithromycin; elevating the temperature of the roxithromycin to above the melting point thereof; and reducing the temperature of the melt sufficiently to allow it to set into an amorphous non-crystalline glass form (Form-ll) of roxithromycin having relatively increased solubility without decreasing the stability of thereof.Type: ApplicationFiled: December 15, 2010Publication date: February 21, 2013Applicant: North-West UniversityInventors: Wilna Leibenberg, Marique Aucamp, Melgardt M. De Villiers
-
Publication number: 20130045939Abstract: The invention relates to fatty and macrolide derivatives; compositions comprising an effective amount of fatty acid macrolide derivative; and methods for treating or preventing an autoimmune disorders and diseases with inflammation as the underlying etiology comprising the administration of an effective amount of a fatty acid macrolide derivative.Type: ApplicationFiled: March 18, 2011Publication date: February 21, 2013Applicant: CATABASIS PHARMACEUTICALS, INC.Inventors: Chi B. Vu, Jean E. Bemis, Michael R. Jirousek, Jill C. Milne
-
Publication number: 20130045937Abstract: Described herein are pharmaceutical compositions adapted for the parenteral administration of macrolide antibiotics, such as triazole-containing and fluoroketolide antibiotics. Also described herein are methods for their use in the treatment of bacterial, protozoal, and other infections.Type: ApplicationFiled: March 10, 2011Publication date: February 21, 2013Applicant: CEMPRA PHARMACEUTICALS, INC.Inventors: David E. Pereira, Prabhavathi Fernandes
-
Publication number: 20130039869Abstract: Regimen for the treatment of rosacea include the application of an anti-redness composition to at least a portion of the cleansed area of skin afflicted with rosacea. The regimen may include the application of one or more of a polymetal complex, a composition containing metronidazole, and/or a protective composition. Kits containing components useful in performing such regimens are also described.Type: ApplicationFiled: February 8, 2012Publication date: February 14, 2013Applicant: JR CHEM, LLCInventors: Jose E. Ramirez, Hovig Ounanian
-
Publication number: 20130022661Abstract: A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having structural properties so as to aid in the generation of new bone tissue and eventually be reabsorbed in the newly formed bone tissue. This structural and bio-remodable implant reduces, if not eliminates, the need to remove the implantable member from the patient once new bone tissue is formed. A kit including the implantable devices and bone growth material is disclosed. Methods of use are also disclosed.Type: ApplicationFiled: July 21, 2011Publication date: January 24, 2013Applicant: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20130018008Abstract: New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.Type: ApplicationFiled: March 22, 2011Publication date: January 17, 2013Applicant: CEMPRA PHARMACEUTICALS, INC.Inventor: David E. Pereira
-
Patent number: 8354383Abstract: The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.Type: GrantFiled: March 6, 2009Date of Patent: January 15, 2013Assignee: Enanta Pharmaceuticals, Inc.Inventors: In Jong Kim, Tongzhu Liu, Jiang Long, Guoqiang Wang, Yao-Ling Qiu, Heejin Kim, Yanchun Wang, Ly Tam Phan, Yat Sun Or
-
Patent number: 8349806Abstract: The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for over two weeks. The method comprises identifying a subject in need thereof, and topically administering to the eye of the subject a pharmaceutical formulation consisting essentially of an effective amount azithromycin. The present invention further relates to a method for treating dry eye secondary to blepharitis in a subject. The method comprises the steps of: identifying a subject suffering from dry eye secondary to posterior blepharitis, and topically administering to the eye of the subject a pharmaceutical formulation comprising an effective amount of azithromycin. The present invention further relates to method for reducing contact lens intolerance of a subject due to blepharitis or dry eye secondary to blepharitis.Type: GrantFiled: July 10, 2009Date of Patent: January 8, 2013Assignee: Inspire Pharmaceuticals, Inc.Inventors: Kurt E. Brubaker, Romulus K. Brazzell, Reza M. Haque, John C. Ice, Jr., José L. Boyer, Joseph B. Boyd, Robert J. Dempsey
-
Patent number: 8349816Abstract: The present invention relates to use of an antibacterial agent in the manufacture of a medicament for the treatment of osteoarthritis, more particularly for the treatment of a bacterial infection which is responsible for osteoarthritis. Also described are methods for the diagnosis of osteoarthritis through the detection of certain bacteria in an affected joint of a patient with osteoarthritis.Type: GrantFiled: February 7, 2007Date of Patent: January 8, 2013Assignee: Orthogenics ASInventor: Mohamed Raafat El-Gewely
-
Patent number: 8343936Abstract: Described herein are novel macrolides, the preparation of novel macrolides, the use of novel macrolides for preventing, treating, or ameliorating various conditions, and the use of novel macrolides as antibacterial agents.Type: GrantFiled: July 26, 2011Date of Patent: January 1, 2013Assignee: Optimer Pharmaceuticals, Inc.Inventors: Jonathan Duffield, Youe-Kong Shue, Yoshitaka Ichikawa, Chan-Kou Hwang
-
Patent number: 8343511Abstract: The present disclosure provides improved compositions comprising rifabutin, clarithromycin, and clofazimine for use in the treatment of Inflammatory Bowel Diseases. In one instance, the compositions may comprise a formulation of rifabutin, clarithromycin, and clofazimine in a single dosage form, such as a capsule, tablet, etc., with one or more specific excipients.Type: GrantFiled: February 5, 2009Date of Patent: January 1, 2013Assignee: Red Hill Biopharma Ltd.Inventors: Thomas Julius Borody, Patrick Gosselin
-
Publication number: 20120328549Abstract: The present invention provides oil compositions and associated methods and reagents, particularly useful for the treatment of dermatologic conditions. In some embodiments, provided compositions are formulated for and achieve transdermal delivery, for example by topical administration.Type: ApplicationFiled: January 23, 2012Publication date: December 27, 2012Applicant: ANTERIOS, INC.Inventors: Jonathan EDELSON, Timothy KOTYLA, Klaus THEOBALD
-
Publication number: 20120329741Abstract: Compounds of Formula I or II, and methods of making and using thereof, are described herein. M represents a macrolide subunit, E is a C1-6 group, optionally containing one or more heteroatoms, D is an alkyl or aryl group, A is a linking group connected to D, B is an alkyl, alkylaryl or alkylheteroaryl spacer group, ZBG is a Zinc Binding Group, R1, R2 and R4 are independently are selected from hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C1-6 alkanoate group, a C2-6 carbamate group, a C2-6 carbonate group, a C2-6 carbamate group, or a C2-6 thiocarbamate group, R3 is hydrogen or —OR5, R5 is selected from a group consisting of Hydrogen, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, C1-6 alkanoate group, C2-6 carbamate group, C2-6 carbonate group, C2-6 carbamate group, or C2-6 thiocarbamate group.Type: ApplicationFiled: May 25, 2012Publication date: December 27, 2012Inventors: Adegboyega Oyelere, Subhasish Tapadar
-
Publication number: 20120321579Abstract: The present invention provides surfactant compositions and associated methods and reagents, particularly useful for the treatment of dermatologic conditions. In some embodiments, provided compositions are formulated for and achieve transdermal delivery, for example by topical administration.Type: ApplicationFiled: January 23, 2012Publication date: December 20, 2012Applicant: ANTERIOS, INC.Inventors: Jonathan EDELSON, Timothy KOTYLA, Klaus THEOBALD
-
Publication number: 20120316106Abstract: Improved antibiotic analogs, and synergistic combinations of antibiotics designed based on structural crystallographic analysis, are provided as well as pharmaceutical compositions that include these improved analogs and synergistic combinations, along with methods for their production and use. The synergistic combinations target neighboring sites in the ribosome demonstrating the importance of the corresponding ribosomal sites for development of clinically-relevant synergistic antibiotics.Type: ApplicationFiled: December 29, 2010Publication date: December 13, 2012Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Ada Yonath, Chen Davidovich, Ella Zimmerman, Anat Bashan, Tamar Auerbach, Matthew Belousoff, Liqun Xiong, Dorota Klepacki, Alexander S. Mankin
-
Patent number: 8329663Abstract: The present disclosure provides compositions and methods for the treatment and elimination of chronic intracellular infections in cells or organisms. The compositions may include one or more acidic substances and one or more antimicrobial substances, administered in combination or separately. The methods may include administering an amount of one or more such compositions to an infected cell or organism for a period of time ranging from days to years, until the infection is substantially eliminated.Type: GrantFiled: January 31, 2009Date of Patent: December 11, 2012Inventor: Paul Griffin
-
Publication number: 20120308633Abstract: This invention uses mesoporous silica nanoparticles and other nanostructured materials to formulate polyacrylate-based bone cement for achieving an enhanced and controlled elution of active ingredients such as antibiotics. This invention overcomes the limitation of low antibiotic release from commercial polyacrylate-based bone cements using for example, PMMA. In certain aspects, the formulation enables a sustained release of antibiotics from the bone cement over a period of 80 days and achieves 70% of total drug release, whereas the commercial antibiotic bone cement (e.g., SmartSet GHV) only releases about 5% of the antibiotics on the first day and subsequently an almost negligible amount. In addition, the mechanical properties of our formulated bone cements are well retained. The inventive bone cement exhibits good antibacterial properties and has very low cytotoxicity to mouse fibroblast cells.Type: ApplicationFiled: June 1, 2012Publication date: December 6, 2012Applicant: Agency for Science, Technology and ResearchInventors: Shen Shou-Cang, Ng Wai Kiong, Leonard Chia, Reginald Tan
-
Publication number: 20120301422Abstract: The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism.Type: ApplicationFiled: January 16, 2003Publication date: November 29, 2012Inventor: Petrus Johannes Meyer
-
Publication number: 20120301434Abstract: The present invention discloses polypeptides with antibacterial properties and use said polypeptides and/or polynucleotides encoding said polypeptides in the preparation of medicament for the treatment of infectious diseases. The inventors also provide vectors encoding and adapted for expression of the polypeptides and polynucleotides of the invention. The vectors may be used in the preparation of a medicament for the treatment of bacterial infections. Further, the vector of the invention may be used to reduce the load of bacteria in food and/or feed.Type: ApplicationFiled: October 4, 2010Publication date: November 29, 2012Applicant: OSLO UNIVERSITETSSYKEHUS HFInventors: Ragnhild Weel-Sneve, James Alexander Booth, Magnar Bjørås, Knut Ivan Kristiansen
-
Publication number: 20120301546Abstract: The present disclosure describes a delivery device for administration of nutraceuticals or pharmaceuticals, which device contains a soft gel shell comprising a gelatin-based water soluble film forming polymer, an acid insoluble polymer, and at least one reducing sugar and water, including processes, gel mixtures used for device production, and coatings containing such gel mixtures.Type: ApplicationFiled: May 26, 2011Publication date: November 29, 2012Inventor: Emadeldin M. Hassan
-
Publication number: 20120283175Abstract: The present invention provides a methods and pharmaceutical compositions useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, a synergistic combination of an inhibitor of LpxC and second antibacterial agent.Type: ApplicationFiled: November 4, 2011Publication date: November 8, 2012Applicant: Achaogen, Inc.Inventors: Phillip A. Patten, Eliana Saxon Armstrong
-
Publication number: 20120277174Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.Type: ApplicationFiled: August 13, 2010Publication date: November 1, 2012Applicant: BASILEA PHARMACEUTICA AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Patent number: 8299035Abstract: A 10a-azalide compound having a 4-membered ring structure crosslinked at the 10a- and 12-positions, which is represented by the formula (I), and is effective on even Haemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneunococci and streptococci).Type: GrantFiled: May 15, 2009Date of Patent: October 30, 2012Assignees: Taisho Pharmaceutucal Co., Ltd., Meiji Seika Pharma Co., Ltd.Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Jun Kurosaka, Naoki Sasamoto, Masato Kashimura, Tomoaki Miura, Kenichi Kanemoto, Satoshi Yoshida, Kou Kumura, Keiichi Ajito
-
Patent number: 8293715Abstract: A novel 10a-azalide compound crosslinked at the 10a- and 12-positions, which is represented by the following formula, and is effective on even Hemophilus influenzae, or erythromycin resistant bacteria (e.g., resistant pneumococci and streptococci).Type: GrantFiled: August 6, 2008Date of Patent: October 23, 2012Assignees: Taisho Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd.Inventors: Tomohiro Sugimoto, Kanako Yamamoto, Jun Kurosaka, Naoki Sasamoto, Masato Kashimura, Tomoaki Miura, Kenichi Kanemoto, Tomohiro Ozawa, Ken Chikauchi, Eiki Shitara
-
Publication number: 20120258177Abstract: The present invention provides microcapsules comprising benzoyl peroxide and topical compositions comprising them, optionally along with other active ingredients, particularly for the treatment of acne.Type: ApplicationFiled: October 7, 2010Publication date: October 11, 2012Inventors: Danny Goldstein, Tal Sade, Yuri Yasman, Olga Privalova, Lior Benaltabet
-
Publication number: 20120252747Abstract: The present invention provides macrocyclic compounds useful as therapeutic agents of the formula: or a pharmaceutically acceptable salt, ester, N-oxide, or prodrug thereof, wherein T, R1, R2, R3, D, E, F, and G are as defined herein. More particularly, these compounds are useful as anti-infective, antiproliferative, anti-inflammatory and prokinetic agents.Type: ApplicationFiled: June 18, 2012Publication date: October 4, 2012Inventors: Jay J. Farmer, Ashoke Bhattacharjee, Yi Chen, Joel A. Goldberg, Joseph A. Ippolito, Zoltan F. Kanyo, Rongliang Lou, Adegboyega K. Oyelere, Edward C. Sherer, Joyce A. Sutcliffe, Deping Wang, Yusheng Wu, Yanming Du
-
Publication number: 20120251464Abstract: Compounds are described that are effective in enhancing the efficacy of antimicrobial agents. Also described are methods of using such compounds and compositions that include such compounds. The composition includes a chalcone compound and, optionally, an antimicrobial agent.Type: ApplicationFiled: December 18, 2009Publication date: October 4, 2012Applicants: Indian Institute of Integrative Medicine, Colgate-Palmolive ComplanyInventors: Ravi Subramanyam, Laurence Du-Thumm, Ghulam Nabi Qazi, Inshad Ali Khan, Krishan Avtar Suri, Naresh Kumar Satti, Furqan Ali, Nitin Pal Kalia
-
Patent number: 8278281Abstract: The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. The compounds have the following structure: wherein T is the macrocyclic part.Type: GrantFiled: August 24, 2006Date of Patent: October 2, 2012Assignee: Rib-X Pharmaceuticals, Inc.Inventors: Ashoke Bhattacharjee, Zoltan F. Kanyo, Edward C. Sherer
-
Publication number: 20120244214Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.Type: ApplicationFiled: June 5, 2012Publication date: September 27, 2012Inventor: Jerome B. Zeldis
-
Publication number: 20120245107Abstract: The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents.Type: ApplicationFiled: June 7, 2012Publication date: September 27, 2012Inventors: William Henry, Henk-Andre Kroon, Linda Summerton
-
Patent number: 8273720Abstract: The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.Type: GrantFiled: February 18, 2009Date of Patent: September 25, 2012Assignee: Enanta Pharmaceuticals, Inc.Inventors: In Jong Kim, Tongzhu Liu, Heejin Kim, Yanchun Wang, Yao-Ling Qiu, Ly Tam Phan, Yat Sun Or
-
Publication number: 20120231995Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.Type: ApplicationFiled: May 17, 2012Publication date: September 13, 2012Applicant: HELPERBY THERAPEUTICS LIMITEDInventors: Petra Helga Beck, Marc Barry Brown, David Edward Clark, Anthony Coates, Hazel Joan Dyke, Yanmin Hu, Derek John Londesbrough, Keith Mills, Thomas David Pallin, Gary Patrick Reid, Gerlinda Stoddart